Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.

Slaton, J W

Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Sep 2001 - 2840-53 p. digital

Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.

1078-0432


Adult
Aged
Animals
Antineoplastic Agents, Phytogenic--therapeutic use
Biopsy
Blood Vessels--drug effects
Blotting, Northern
Cadherins--analysis
Carcinoma, Transitional Cell--drug therapy
Cell Movement--drug effects
Collagen
Collagenases--drug effects
Dose-Response Relationship, Drug
Drug Combinations
Drug Synergism
Endothelial Growth Factors--genetics
Female
Fibroblast Growth Factor 2--genetics
Follow-Up Studies
Gene Expression Regulation, Neoplastic--drug effects
Humans
In Situ Hybridization
Interferon-alpha--therapeutic use
Interleukin-8--genetics
Laminin
Lymphokines--genetics
Male
Matrix Metalloproteinase 9--analysis
Mice
Mice, Inbred BALB C
Mice, Nude
Middle Aged
Neoplasm Invasiveness
Neoplasm Metastasis--pathology
Neoplasm Staging
Neovascularization, Pathologic--prevention & control
Paclitaxel--therapeutic use
Prognosis
Proteoglycans
RNA, Messenger--drug effects
Tumor Cells, Cultured
Urinary Bladder--chemistry
Urinary Bladder Neoplasms--drug therapy
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
Xenograft Model Antitumor Assays